Form: SCHEDULE 13G/A

Statement of Beneficial Ownership by Certain Investors

November 14, 2025






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  Includes (i) 304,916 shares of common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 45,534 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 1,178,750 shares of Common Stock underlying prefunded and milestone warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC as of September 30, 2025. Excludes 2,764,992 shares of Common Stock underlying prefunded and milestone warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. Based on 14,128,562 shares of Common Stock of Grace Therapeutics, Inc. (the "Issuer") outstanding as of September 30, 2025, reported in the Issuer's 10Q for the quarterly period ended September 30, 2025, filed with the SEC on November 13, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  Includes (i) 304,916 shares of common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP and (ii) 1,229,338 shares of Common Stock underlying prefunded and milestone warrants held by ADAR1 Partners, LP as of September 30, 2025. Excludes 2,248,614 shares of Common Stock underlying prefunded and milestone warrants held by ADAR1 Partners, the exchange and exercise of which are subject to the 9.99% beneficial ownership limitations. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. Based on 14,128,562 shares of Common Stock of Grace Therapeutics, Inc. (the "Issuer") outstanding as of September 30, 2025, reported in the Issuer's 10Q for the quarterly period ended September 30, 2025, filed with the SEC on November 13, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  Includes (i) 304,916 shares of common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 45,534 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 1,178,750 shares of Common Stock underlying prefunded and milestone warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC as of September 30, 2025. Excludes 2,764,992 shares of Common Stock underlying prefunded and milestone warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. Based on 14,128,562 shares of Common Stock of Grace Therapeutics, Inc. (the "Issuer") outstanding as of September 30, 2025, reported in the Issuer's 10Q for the quarterly period ended September 30, 2025, filed with the SEC on November 13, 2025.


SCHEDULE 13G



 
ADAR1 Capital Management, LLC
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:11/14/2025
 
ADAR1 Capital Management GP, LLC
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:11/14/2025
 
Daniel Schneeberger
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, in his individual capacity
Date:11/14/2025